RecruitingDemyelinating DisordersMCIAlzheimer's Disease (AD)
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Eligible age
18–90 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Sponsor: Yale University
Where it's recruiting
Connecticut
New Haven
Source: ClinicalTrials.gov · NCT06999434 · last updated 2025-05-31